Gufic Biosciences has doubled down on its biotechnology ambitions, announcing a further investment in Western Australia-based immunotherapy firm Selvax, in a strategic push aligned with its “Vision 2030” roadmap.
The move strengthens Gufic’s foothold in next-generation cancer research, particularly in immunology-driven treatments targeting solid tumors.
On April 28, 2026, the company subscribed to 378,350 ordinary shares in Selvax at AUD 20 cents per share, with a total cash outlay of USD 50,000. Following the transaction, Gufic’s total stake in the Australian biotech now stands at 1,685,350 shares.
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology, including treatments for dogs. Its platform targets large solid tumors and is designed around proprietary immunology technology.
The company’s therapeutic approach is built on three key mechanisms:
1. Targeted Delivery: Focusing specifically on tumor sites to reduce dosages and minimize toxicity.
2. Systemic Response: Treating one location to trigger a whole-body immune response, potentially clearing untreated metastatic tumors.
3. Long-term Memory: Inducing immunological memory to protect patients against cancer recurrence."
The pipeline also carries broad oncology potential, with applications across sarcomas, lung, pancreatic, breast, and colorectal cancers.
Gufic views the investment as a strategic entry into high-growth immunotherapy markets. The company highlighted multiple benefits from the deal, including access to proprietary research, diversification into oncology, and deeper engagement with the Australian biotech ecosystem.
Financially, Selvax has posted gradual revenue growth over the past three fiscal years ending June 30, reporting AUD 220,435 in 2023, AUD 248,817 in 2024, and AUD 356,972 in 2025.
The development underscores Gufic’s steady expansion beyond pharmaceuticals into advanced oncology innovation, as it builds a more global footprint in biotech research and investment.
